iCAD to Participate in the 14th Annual Craig-Hallum Alpha Select Conference
14 November 2023 - 2:00PM
iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a
world where cancer can’t hide by providing clinically proven
AI-powered breast health solutions, today announced that Dana
Brown, President and Chief Executive Officer and Eric Lonnqvist,
Chief Financial Officer, will participate at the 14th Annual
Craig-Hallum Alpha Select Conference on Thursday, November 16th.
The conference will be held at the Sheraton New York Times Square
in New York City.
Management is scheduled to host one-on-one meetings
with investors and attendees during the conference. Investors
interested in arranging one-on-one meetings should contact their
Craig-Hallum conference representative.
About iCADiCAD, Inc. (NASDAQ:
ICAD) is a global leader on a mission to create a world where
cancer can’t hide by providing clinically proven AI-powered
solutions that enable medical providers to accurately and reliably
detect cancer earlier and improve patient outcomes. Headquartered
in Nashua, NH., iCAD’s industry-leading ProFound Breast Health
Suite provides AI-powered mammography analysis for breast cancer
detection, density assessment and risk evaluation. The ProFound
Breast Health Suite is cleared by the U.S. Food & Drug
Administration (FDA) and has received CE mark and Health Canada
licensing. Used by thousands of providers serving millions of
patients, ProFound is available in over 50 countries. For more
information, visit www.icadmed.com.
Forward-Looking StatementsCertain
statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the expansion of access to the Company’s products,
improvement of performance, acceleration of adoption, expected
benefits of ProFound AI®, the benefits of the Company’s products,
and future prospects for the Company’s technology platforms and
products. Such forward-looking statements involve a number of known
and unknown risks, uncertainties and other factors which may cause
the actual results, performance, or achievements of the Company to
be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited, to the
Company’s ability to achieve business and strategic objectives, the
willingness of patients to undergo mammography screening in light
of risks of potential exposure to Covid-19, whether mammography
screening will be treated as an essential procedure, whether
ProFound AI will improve reading efficiency, improve specificity
and sensitivity, reduce false positives and otherwise prove to be
more beneficial for patients and clinicians, the impact of supply
and manufacturing constraints or difficulties on our ability to
fulfill our orders, uncertainty of future sales levels, to defend
itself in litigation matters, protection of patents and other
proprietary rights, product market acceptance, possible
technological obsolescence of products, increased competition,
government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed
in the Company’s filings with the Securities and Exchange
Commission. The words “believe,” “demonstrate,” “intend,” “expect,”
“estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and
similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made.
The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the
disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.
Media Inquiries:pr@icadmed.com
Investor Inquiries:ir@icadmed.com
Icad (NASDAQ:ICAD)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Icad (NASDAQ:ICAD)
Historical Stock Chart
Von Mai 2023 bis Mai 2024